Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/21/2025 | $10.00 | Buy | TD Cowen |
11/12/2024 | $3.00 | Neutral | UBS |
10/27/2023 | $12.00 | Buy | Canaccord Genuity |
5/31/2023 | $11.00 | Buy | ROTH MKM |
5/19/2023 | Sell → Buy | Societe Generale | |
3/17/2023 | $27.00 | Buy | Stifel |
11/15/2022 | Buy → Sell | Societe Generale | |
11/22/2021 | $40.00 → $42.00 | Buy | HC Wainwright & Co. |
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder
The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PHLanifibranor was observed to decrease portal pressure by improving Liver Sinusoidal Endothelial Cell (LSEC) dysfunction and fibrosis, and by directly targeting the splanchnic vasculature through its anti-angiogenetic effectsThese findings suggest that lanifibranor may be a promising therapeutic candidate that could potentially address PH-related complications typically associated with MASLD, MASH, and other advanced chronic liver diseases, including cirrhosis Daix (France), New York City (New York, United States), February 26, 2025 – Inventiva (Euronext Par
SCHEDULE 13G - Inventiva S.A. (0001756594) (Subject)
6-K - Inventiva S.A. (0001756594) (Filer)
6-K - Inventiva S.A. (0001756594) (Filer)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
SC 13D/A - Inventiva S.A. (0001756594) (Subject)
Inventiva secures €21.4 million leading to completion of the first tranche of the financing for c. €116 million, part of the multi-tranche equity financing of up to €348 million announced on October 14, 2024. Proceeds from the completed first tranche to be primarily used to advance Inventiva's Phase III, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Appointment of Mark Pruzanski as new Chairman of the Board of Directors and Srinivas Akkaraju as new member of the Board of Directors. Daix (France), New York City (New York, United States), December 16, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinica
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million in milestone payments relating to equity financing pursuant to amendment to license and collaboration agreement with CTTQ.Proceeds from financing to be primarily used to advance Inventiva's Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. More than 1,100 patients randomized in the NATiV3 study evaluating lanifibranor for the treatment of noncirrhotic MASH, with completion of enrollment projected in 1H 2025.Appointment to the Board of Directors of Mark Pruzanski, MD,
Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH") and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne's appointment will be submitted to the shareholders for ratification at the next general shareholder meeting. Frédéric Cren, Chairman, Chief Executive Officer, and cofounder of Inventiva: "We are extre
TD Cowen initiated coverage of Inventiva with a rating of Buy and set a new price target of $10.00
UBS initiated coverage of Inventiva with a rating of Neutral and set a new price target of $3.00
Canaccord Genuity initiated coverage of Inventiva with a rating of Buy and set a new price target of $12.00
Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research activities and reducing the workforce by 50% Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical c
Daix (France), New York City (New York, United States), March 19, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company's 2024 full-year financial results on Thursday, March 27, 2025. Inventiva's 2024 full-year financial results will be published on Wednesday, March 26, 2025 at 4:00 pm (New York), 9:00 pm (Paris). Frédéric Cren, CEO and cofounder
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial.Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial.Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarkers comparable to the Phase IIb, NATIVE, study results and that weight gain plateaus and stabilizes starting at week 24 to 36.Last patient randomization is anticipated in the first half of 20